Table 2. Crude and adjusted OR and HR (95% confidence interval) for all leukaemia, acute lymphoblastic leukaemia, CNS cancers and both types across radon exposure level and age in two models across age groups.
| |
|
<1 year |
0–4 years |
0–15 years |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cancer type | Radon (Bq m−3) | No of cases | Crude OR | Model I OR | Model II OR | No. of cases | Crude HR | Model I HR | Model II HR | No of cases | Crude HR | Model I HR | Model II HR |
| All lleukaemia |
<50 |
99 |
Ref. |
Ref. |
Ref. |
99 |
Ref. |
Ref. |
Ref. |
95 |
Ref. |
Ref. |
Ref. |
| |
50–100 |
205 |
1.21 (0.95–1.54) |
1.15 (0.90–1.48) |
1.12 (0.88–1.44) |
207 |
1.12 (0.88–1.42) |
1.07 (0.84–1.37) |
1.04 (0.81–1.34) |
209 |
1.05 (0.82–1.33) |
1.00 (0.78–1.29) |
0.97 (0.76–1.25) |
| |
>100 |
127 |
1.18 (0.91–1.55) |
1.13 (0.87–1.48) |
1.11 (0.85–1.46) |
125 |
1.10 (0.84–1.43) |
1.07 (0.82–1.40) |
1.05 (0.800–1.37) |
127 |
1.06 (0.82–1.39 |
1.03 (0.79–1.36) |
1.02 (0.78–1.34) |
| |
Per 100 Bq m−3a |
|
1.00 (0.87–1.14) |
0.99 (0.87–1.14) |
1.00 (0.87–1.14) |
|
0.99 (0.86–1.13) |
0.99 (0.86–1.13) |
0.99 (0.86–1.14) |
|
0.99 (0.86–1.13) |
0.99 (0.86–1.14) |
1.00 (0.87–1.15) |
| Acute lymphoblastic leukaemia |
<50 |
79 |
Ref. |
Ref. |
Ref. |
78 |
Ref. |
Ref. |
Ref. |
74 |
Ref. |
Ref. |
Ref. |
| |
50–100 |
153 |
1.13 (0.86–1.49) |
1.08 (0.82–1.43) |
1.03 (0.78–1.36) |
155 |
1.06 (0.81–1.39) |
1.02 (0.77–1.35) |
0.97 (0.74–1.29) |
157 |
1.01 (0.76–1.33) |
0.97 (0.73–1.28) |
0.93 (0.70–1.23) |
| |
100 |
92 |
1.07 (0.80–1.46) |
1.04 (0.77–1.41) |
1.02 (0.75–1.39) |
91 |
1.02 (0.75–1.37) |
0.98 (0.72–1.34) |
1.00 (0.70–1.31) |
93 |
1.00 (0.74–1.36) |
0.70 (0.71–1.32) |
0.95 (0.69–1.29) |
| |
Per 100 Bq m−3a |
|
0.97 (0.83–1.14) |
0.97 (0.83–1.14) |
0.98 (0.83–1.15) |
|
0.96 (0.82–1.13) |
0.96 (0.23–1.13) |
0.97 (0.82–1.14) |
|
0.97 (0.82–1.14) |
0.97 (0.82–1.14) |
0.97 (0.83–1.15) |
| CNS cancer |
<50 |
100 |
Ref. |
Ref. |
Ref. |
98 |
Ref. |
Ref. |
Ref. |
92 |
Ref. |
Ref. |
Ref. |
| |
50–100 |
172 |
1.00 (0.79–1.29) |
0.95 (0.74–1.23) |
0.96 (0.74–1.24) |
174 |
0.95 (0.74–1.22) |
0.90 (0.70–1.16) |
0.90 (0.69–1.16) |
182 |
0.94 (0.73–1.21) |
0.88 (0.68–1.14) |
0.88 (0.68–1.14) |
| |
>100 |
145 |
1.34 (1.04–1.73) |
1.25 (0.96–1.62) |
1.27 (0.97–1.65) |
145 |
1.29 (1.00–1.66) |
1.22 (0.94–1.59) |
1.21 (0.93–1.58) |
143 |
1.23 (0.95–1.60) |
1.16 (0.89–1.51) |
1.15 (0.87–1.50) |
| |
Per 100 Bq m−3a |
|
1.17 (1.04–1.32) |
1.14 (1.00–1.29) |
1.13 (1.00–1.29) |
|
1.17 (1.04–1.32) |
1.14 (1.00–1.29) |
1.14 (1.00–1.29) |
|
1.15 (1.02–1.30) |
1.12 (0.99–1.27) |
1.13 (0.99–1.28) |
| Leukaemia and CNS cancer |
<50 |
199 |
Ref. |
Ref. |
Ref. |
197 |
Ref. |
Ref. |
Ref. |
187 |
Ref. |
Ref. |
Ref. |
| |
50–100 |
377 |
1.10 (0.93–1.32) |
1.05 (0.88–1.26) |
1.04 (0.87–1.25) |
381 |
1.03 (0.87–1.23) |
0.99 (0.83–1.18) |
0.97 (0.81–1.16) |
391 |
0.99 (0.83–1.18) |
0.94 (0.79–1.13) |
0.93 (0.78–1.11) |
| |
>100 |
272 |
1.26 (1.05–1.52) |
1.19 (0.99–1.44) |
1.19 (0.98–1.44) |
270 |
1.19 (0.99–1.43) |
1.15 (0.95–1.38) |
1.13 (0.93–1.36) |
270 |
1.15 (0.95–1.38) |
1.10 (0.91–1.32) |
1.08 (0.89–1.31) |
| Per 100 Bq m−3a | 1.09 (0.99–1.19) | 1.07 (0.98–1.17) | 1.07 (0.97–1.17) | 1.08 (0.99–1.18) | 1.08 (0.81–1.15) | 1.07 (0.97–1.17) | 1.07 (0.98–1.17) | 1.06 (0.96–1.16) | 1.06 (0.97–1.17) | ||||
Abbreviations: HR=hazard ratio; OR=odds ratio.
Model I is adjusted for socioeconomic status (family income, mother and father's level of education).
Model II is adjusted for all variables (parity, birth weight, sex, congenital malformations, family income, mother and father's level of education).
a
Grouped into five groups by increments of 100 Bq m−3.